Clinical Report: The Role of the IGF System in the Aging Process

Overview

The insulin-like growth factor (IGF) system plays a critical role in the aging process through complex interactions involving receptors, ligands, binding proteins, and regulatory proteinases. Evidence from cellular senescence, model organisms, and age-related diseases highlights IGF signaling as a potential driver and therapeutic target for promoting healthy aging.

Background

The IGF system is evolutionarily conserved and includes multiple components such as IGF-I and IGF-II ligands, IGF receptors (IGF-IR and IGF-IIR), high-affinity IGF-binding proteins (IGFBPs), and regulatory proteinases like PAPP-A and PAPP-A2. IGF-IR mediates key intracellular signaling pathways influencing cell survival and proliferation, while IGF-IIR primarily attenuates IGF signaling. IGFBPs modulate IGF bioavailability and activity, with their function further regulated by proteolytic cleavage and endogenous inhibitors such as stanniocalcins. Understanding the extracellular regulation of IGF activity is essential to elucidate its role in aging and related pathologies.

Data Highlights

The IGF system components include:
- IGF-I and IGF-II ligands
- Type I IGF receptor (IGF-IR) with α and β subunits initiating PI3K/Akt and MAPK pathways
- Type II IGF receptor (IGF-IIR) functioning in IGF-II clearance
- Six high-affinity IGF-binding proteins (IGFBP-1 to IGFBP-6)
- Proteolytic enzymes PAPP-A and PAPP-A2 that cleave IGFBPs to regulate IGF availability
- Stanniocalcins (STC1 and STC2) as potent inhibitors of PAPP-A and PAPP-A2 activity

Key Findings

• IGF signaling is intricately involved in fundamental aging mechanisms including cellular senescence.
• IGF-IR activation triggers intracellular pathways (PI3K/Akt and MAPK) that regulate cell survival and proliferation.
• IGFBPs modulate IGF activity by binding IGFs and are regulated by proteolytic cleavage, primarily by PAPP-A and PAPP-A2.
• PAPP-A enhances local IGF signaling by cleaving IGFBPs in the tissue microenvironment, while PAPP-A2 acts mainly in circulation.
• Stanniocalcins inhibit PAPP-A and PAPP-A2, thereby modulating IGF bioavailability and signaling.
• Alterations in IGF system components are implicated in age-related diseases such as pulmonary fibrosis, Alzheimer’s disease, and macular degeneration.

Clinical Implications

Targeting components of the IGF system, such as modulating PAPP-A activity or IGFBP interactions, may offer novel therapeutic strategies to mitigate aging-related cellular dysfunction and disease. Understanding the balance between IGF signaling activation and inhibition is crucial for developing interventions aimed at promoting healthy aging and treating age-associated disorders.

Conclusion

The IGF system represents a complex but critical regulator of aging processes and age-related diseases. Continued research into its extracellular regulation and signaling pathways holds promise for identifying new targets to promote longevity and healthy aging.

References

1. General IGF System Reviews (1-6)
2. Original identification of PAPP-A antigen in pregnancy (8)
3. Stanniocalcin inhibition of PAPP-A and PAPP-A2 (9-11)